Nuvilex, Inc. and Celgene, Corp. Can Both Replace Eli Lilly's Cancer Drug Gemzar

Nuvilex, Inc. and Celgene, Corp. Can Both Replace Eli Lilly's Cancer Drug Gemzar 
NEW YORK, NY -- (Marketwired) -- 05/20/13 --  The race is on, and
patients with advanced stage, inoperable pancreatic cancer will be
the recipients of the winner's treatment. Two biotechnology companies
are registering impressive data in each of their own pancreatic
cancer trials, so impressive in fact, the NYSE's Eli Lilly is surely
feeling its long time reign as the current standard single-drug
treatment for the disease being threatened. Nuvilex, Inc. (OTCQB:
NVLX) and NASDAQ's Celgene Corp. are the two biotech firms applying
the heat. 
One thing is for sure -- pancreatic cancer drugs are big business.
Eli Lilly & Co.'s sales of its blockbuster cancer drug gemcitabine
(Gemzar(R)) have averaged close to $1.5-billion per year globally
since its approval back in 1996. Gemzar is the only drug approved by
the FDA as a single agent for the treatment of advanced, inoperable
pancreatic cancer. According to Indianapolis-based Eli Lilly, Gemzar
is a nucleoside analogue that interferes with the process of DNA
production; thereby preventing cancer cells from replicating and, in
turn, slows or stops tumor growth. The drug is the worldwide standard
of care as a single agent for pancreatic cancer, and it is the "base"
upon which combination chemotherapy treatments for the disease is
being built. 
While Gemzar has been the go-to treatment for pancreatic cancer
patients for years that might be about ready to change, and the best
news of all will be for those who suffer from the tough to treat
disease and are in desperate need for better therapies. Both Nuvilex
and Celgene are producing better data with their treatments in
clinical trials as compared to the data offered up by Gemzar. 
Continue reading this Article at 
About Stock House Group
 Stock House Group is a full service
Investment Relations firm specializing in Awareness, Research, and
Content Development. The firm offers a platform that allows CEOs to
tell their story through the press with Feature Articles, Research
Reports, and CEO Interviews. At the same time, Stock House Group is
building a library of Research for Investors to use that allows them
to get more informed on small cap stocks. For more information visit
Stock House Group at  
Stock House Group
(646) 397-4020 
Press spacebar to pause and continue. Press esc to stop.